Global Antibiotic Resistance Market by Disease, Pathogen, Drug Class (Oxazolidinone, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination therapies, others), Region, Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast 2018 to 2025
Published On: January 2019
 
Report ID:362194
 
 
Pages: N/A




Global antibiotic resistance market is expected to reach USD 8.21 Billion in 2017 to USD 13.16 Billion by 2025 at a CAGR of 6.20% from 2018 to 2025. Emergence of multidrug resistance pathogen and wide distribution of anti-MRSA drugs to combat the increasing resistance against antibiotic resistance along with a growing demand for generic drugs are primarily driving the market.

Market Overview:

Antibiotics are antimicrobial substance which is used to fight against the bacterial infection. They are also used to cure many conditions such as strep throat, sinus infections, urinary tract infections, ear infections, pneumonia, skin infections, and others. Antibiotics are classified on the basis of chemical structures, spectrum of activity and mode of action. The ability to resist the bacterial infection is termed as antibiotics resistance. It is a major concern worldwide. Major pharmaceutical companies on the forefront and involved in development of broad spectrum antibiotics. For instance, in 2018, Acurx Pharmaceuticals introduced ACX-362E, which is the US Food and Drug Administration (FDA) approved antibiotic candidate, designated as Qualified Infectious Disease Product (QIDP) with Clostridium difficile infection (CDI).

Report Description:

  • The base year for the study has been considered 2017, historic year 2015 and 2016 and, the forecast period considered is from 2018 to 2025. The antibiotic resistance market is analysed on the basis of value (USD Billion).
  • The study delivers a comprehensive analysis of global antibiotic resistance market by disease, pathogen, drug class and regions.
  • The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2018 to 2025.
  • Porter’s Five Forces model is used in order to recognize the competitive scenario in the global antibiotic resistance market. This report incorporates the industry analysis which is focused on providing an extensive view of the antibiotic resistance market.
  • The study also includes attractiveness analysis of disease, pathogen, drug class, and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
  • The report provides company profile of the key players operating in the antibiotic resistance market and a comparative analysis based on their business overviews, product offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
  • The market estimates have been evaluated by considering the effect of different political, economic, social, technological and legal factors which are based on our extensive secondary research, primary research, and in-house databases.

Market Dynamics:

Drivers:

  • Growing demand of generic drugs
  • High burden of antibiotic-resistant infections
  • Emergence of multi-drug resistant pathogens

Restraints:

  • Lack of Investment from major market players

Opportunities:

  • The policies for the development of new therapies for growing burden and severity of antibiotic-resistant infections

Challenges:

  • Increasing resistance against antibiotics associated with product recalls
  • Limited number of manufacturers in the field of antibiotic resistance.

Global Antibiotic Resistance Market Key Findings:

All the segments have been analysed on global, regional and country basis. The study includes the analysis of more than 30 countries for each segment.

Segmentation Analysis:

The antibiotic resistance market is segmented on the basis disease, pathogen and drug class.

  • The disease segment is classified into cUTI, cIAI, BSI, CDI, ABSSSI, HABP/VABP, and CABP. The cUTI segment is dominating the antibiotic resistance market with USD 1.06 Billion in 2017. Owing to treatment cost and limited treatment alternatives for Gram-negative pathogens, which account for majority of infection cases are major contributing factors for the growth of segment.
  • In pathogen segment ESBL-producing held the largest share in 2017 where as CDI, is anticipated to register the highest CAGR of 7.86% during the forecast period. These infections are difficult to be treated due to high resistance to current treatment alternatives. Therefore, impose a high cost burden as physicians are increasingly shifting towards novel antibiotics.
  • Drug class segment is divided into segments such as oxazolidinones, lipoglycopeptides, tetracyclines, cephalosporins, combination therapies, and others. Lipoglycopeptides dominated the segment with largest market share of 21.37% in 2017 due to high usage of these drugs. 

Regional Segmentation Analysis:

The regions analysed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. North America region dominated the global antibiotic resistance market with USD 2.62 Billion in 2017 where as Europe region held the second dominant position in the market.

  • North America region held the largest share due to launch of numerous drugs and the use of novel therapies are some of the factors that led to the growth of antibiotic resistance market in this region.
  • Europe is the second fastest growing region due to growing number of antibiotic-resistant infection contributing to increased antibiotic resistance in the region are creating opportunity for the growth of the market.

Global Antibiotic resistance Market Competitive Analysis:

Key players in the antibiotic resistance market are, Allergan, Melinta Therapeutics., Novartis AG, GlaxoSmithKline PLC, Merck & Co. Inc, Pfizer Inc, Novartis AG, Sanofi SA, Johnson & Johnson, Roche, Shionogi, Lupin and others. Novartis AG, Pfizer and Merck are the top leading players of the market. For instance, in 2018, Novartis entered into a licensing and equity agreement with Boston Pharmaceuticals to develop three novel anti-infective drug candidates against antibiotic-resistant Gram-negative infections.

*All our reports are customizable as per customer requirements

Scope

Key Points

Information

Evaluate Market Potential

Growth Rates (CAGR %)

Value (USD Billion) {Market Size}

USP of Report

Industry and Technology Trends

Market Evolution

Value Chain Analysis

Company Share Analysis

Competitive & Vendor landscape

SWOT Analysis of Each Company

Profit Margin Analysis

Analysis of More than 30 Countries for Each Segment

Base Year

2017

Historical Years

2015-2017

Forecast Period

2018-2025

Regional Analysis

North America, Europe, Asia Pacific, South America, and Middle East and Africa

Countries Analysis

U.S., Canada, Mexico, Germany, France, Sweden, Netherlands, U.K., Italy, Spain, Turkey, Switzerland, Belgium, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Brazil, Saudi Arabia, UAE, Egypt, Nigeria, South Africa

 

This study forecasts revenue and volume growth at global, regional, and country levels from 2015 to 2025. Fior Market Research has segmented the global antibiotic resistance market on the basis of below mentioned segments:

Global Antibiotic Resistance Market, By Disease:

  • Complicated Urinary Tract Infection (cUTI)
  • Complicated Intra-Abdominal Infections (cIAI)
  • Blood Stream Infections (BSI)
  • Clostridium difficile infections (CDI)
  • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
  • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)         
  • Community Acquired Bacterial Pneumonia (CABP)

Global Antibiotic Resistance Market, By Pathogen:

  • Acinetobacter baumannii (Carbapenem-Resistant and ESBL-producing)
  • Pseudomonas aeruginosa (Carbapenem-Resistant)
  • Staphylococcus Aureus (Methicillin-Resistant)
  • E. coli/K. pneumoniae (Carbapenem-Resistant)
  • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
  • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
  • Enterococcus faecium (Vancomycin-Resistant)
  • Haemophilus Influenzae (Ampicillin-Resistant)

Global Antibiotic Resistance Market, By Drug Class:

  • Oxazolidinones
  • Lipoglycopeptides
  • Tetracyclines
  • Cephalosporins
  • Combination therapies
  • Others

Global Antibiotic Resistance Market, By Regions:

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • Sweden
  • Netherlands
  • U.K.
  • Italy
  • Spain
  • Turkey
  • Switzerland
  • Belgium
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Singapore
  • Malaysia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of Asia-Pacific
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Rest of South America
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Nigeria
  • South Africa
  • Rest of  Middle East and Africa
  1. Introduction
    1. Objectives of the Study
    2. Market Definition
    3. Research Scope
    4. Currency
  2. Research Methodology and Assumptions
  3. Executive Summary
  4. Premium Insights
    1. Porter’s Five Forces Analysis
    2. Value Chain Analysis
    3. Top Investment Pockets
      1. Market attractiveness analysis by disease
      2. Market attractiveness analysis by pathogen
      3. Market attractiveness analysis by drug class
      4. Market attractiveness analysis by region
    4. Industry Trends
  5. Market Dynamics
    1. Market Evaluation
    2. Drivers
      1. Growing Demand of Generic Drugs
      2. High Burden of Antibiotic-Resistant Infections
      3. Emergence of Multi-Drug Resistant Pathogens
    3. Restraints
      1. Lack of Investment from Major Market Players
    4. Opportunities
      1. The Policies for The Development of New Therapies for Growing Burden and Severity of Antibiotic-Resistant Infections
    5. Challenges
      1. Increasing Resistance Against Antibiotics Associated with Product Recalls
  6. Global Antibiotic Resistance  Market Analysis and Forecast, By Disease
    1. Segment Overview
    2. Complicated Urinary Tract Infection (cUTI)
    3. Blood Stream Infections (BSI)
    4. Clostridium difficile infections (CDI)
    5. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    6. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
    7. Community Acquired Bacterial Pneumonia (CABP)
  7. Global Antibiotic Resistance  Market Analysis and Forecast, By Pathogen
    1. Segment Overview
    2. Acinetobacter baumannii
    3. Pseudomonas aeruginosa
    4. Staphylococcus Aureus
    5. E. coli/K. pneumonia
    6. Streptococcus pneumonia
    7. Clostridium difficile
    8. Enterococcus faecium
    9. Haemophilus Influenzae
  8. Global Antibiotic Resistance  Market Analysis and Forecast, By Drug Class
    1. Segment Overview
    2. Oxazolidinones
    3. Lipoglycopeptides
    4. Tetracyclines
    5. Cephalosporins
  9. Global Antibiotic Resistance  Market Analysis and Forecast, By Regional Analysis
    1. Segment Overview
    2. North America
      1. U.S.
      2. Canada
      3. Mexico
    3. Europe
      1. Germany
      2. France
      3. Sweden
      4. Netherlands
      5. U.K.
      6. Italy
      7. Spain
      8. Turkey
      9. Switzerland
      10. Belgium
      11. Rest of Europe
    4. Asia-Pacific
      1. Japan
      2. China
      3. India
      4. South Korea
      5. Australia
      6. Singapore
      7. Malaysia
      8. Thailand
      9. Indonesia
      10. Philippines
      11. Rest of Asia-Pacific
    5. South America
      1. Brazil
      2. Argentina
      3. Colombia
      4. Rest of South America
    6. Middle East and Africa
      1. Saudi Arabia
      2. UAE
      3. Egypt
      4. Nigeria
      5. South Africa
      6. Rest of  Middle East and Africa
  10. Global Antibiotic Resistance  Market-Competitive Landscape
    1. Overview
    2. Market Share of Key Players in the Antibiotic Resistance  Market
      1. Global Company Market Share
      2. North America Company Market Share
      3. Europe Company Market Share
      4. APAC Company Market Share
    3. Competitive Situations and Trends
      1. Product Launches and Developments
      2. Partnerships, Collaborations, and Agreements
      3. Mergers & Acquisitions
      4. Expansions
  11. Company Profiles
    1. Pfizer Inc.
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Product Portfolio
      5. Recent Developments
      6. SWOT Analysis
    2. Novartis AG
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Product Portfolio
      5. Recent Developments
      6. SWOT Analysis
    3. Allergan
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Product Portfolio
      5. Recent Developments
      6. SWOT Analysis
    4. Melinta Therapeutics
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Product Portfolio
      5. Recent Developments
      6. SWOT Analysis
    5. Novartis AG
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Product Portfolio
      5. Recent Developments
      6. SWOT Analysis
    6. GlaxoSmithKline PLC
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Product Portfolio
      5. Recent Developments
      6. SWOT Analysis
    7. Merck & Co. Inc
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Product Portfolio
      5. Recent Developments
      6. SWOT Analysis
    8. Sanofi SA
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Product Portfolio
      5. Recent Developments
      6. SWOT Analysis
    9. Johnson & Johnson
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Product Portfolio
      5. Recent Developments
      6. SWOT Analysis
    10. Roche
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Product Portfolio
      5. Recent Developments
      6. SWOT Analysis
    11. Shionogi
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Product Portfolio
      5. Recent Developments
      6. SWOT Analysis
    12. Lupin
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Product Portfolio
      5. Recent Developments
      6. SWOT Analysis
    13. Sun Pharma
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Product Portfolio
      5. Recent Developments
      6. SWOT Analysis
    14. Teva
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Product Portfolio
      5. Recent Developments
      6. SWOT Analysis
    15. Mylan
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Product Portfolio
      5. Recent Developments
      6. SWOT Analysis

 

List of Table

  1. Global Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  2. Global Complicated Urinary Tract Infection Antibiotic Resistance  Market, By Region, 2015–2025 (USD Billion)
  3. Global Complicated Intra-Abdominal Infections Antibiotic Resistance  Market, By Region, 2015–2025 (USD Billion)
  4. Global Blood Stream Infections Antibiotic Resistance  Market, By Region, 2015–2025 (USD Billion)
  5. Global Clostridium difficile infections Antibiotic Resistance  Market, By Region, 2015–2025 (USD Billion)
  6. Global Acute Bacterial Skin and Skin Structure Infections Antibiotic Resistance  Market, BY Region, 2015–2025 (USD Billion)
  7. Global Hospital Acquired Bacterial Pneumonia/Ventilator Antibiotic Resistance  Market, By Region, 2015–2025 (USD Billion)
  8. Global Community Acquired Bacterial Pneumonia Antibiotic Resistance  Market, By Region, 2015–2025 (USD Billion)
  9. Global Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  10. Global Acinetobacter baumannii Antibiotic Resistance  Market, By Region, 2015–2025 (USD Billion)
  11. Global Pseudomonas aeruginosa Antibiotic Resistance  Market, By Region, 2015–2025 (USD Billion)
  12. Global Staphylococcus Aureus Antibiotic Resistance  Market, By Region, 2015–2025 (USD Billion)
  13. Global E. coli/K. pneumoniae Antibiotic Resistance  Market, By Region, 2015–2025 (USD Billion)
  14. Global Streptococcus pneumoniae Antibiotic Resistance  Market, By Region, 2015–2025 (USD Billion)
  15. Global Clostridium difficile Antibiotic Resistance  Market, By Region, 2015–2025 (USD Billion)
  16. Global Enterococcus faecium Antibiotic Resistance  Market, By Region, 2015–2025 (USD Billion)
  17. Global Haemophilus Influenzae Antibiotic Resistance  Market, By Region, 2015–2025 (USD Billion)
  18. Global Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  19. Global Oxazolidinones Antibiotic Resistance  Market, By Region, 2015–2025 (USD Billion)
  20. Global Lipoglycopeptides Antibiotic Resistance  Market, By Region, 2015–2025 (USD Billion)
  21. Global Tetracyclines Antibiotic Resistance  Market, By Region, 2015–2025 (USD Billion)
  22. Global Cephalosporins Antibiotic Resistance  Market, By Region, 2015–2025 (USD Billion)
  23. Global Combination therapies Antibiotic Resistance  Market, By Region, 2015–2025 (USD Billion)
  24. Global Others Antibiotic Resistance  Market, By Region, 2015–2025 (USD Billion)
  25. Global Antibiotic Resistance  Market, By Region, 2015–2025 (USD Billion)
  26. Global Antibiotic Resistance  Market, By North America, 2015–2025 (USD Billion)
  27. North America Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  28. North America Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  29. North America Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  30. U.S. Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  31. U.S. Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  32. U.S. Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  33. Canada Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  34. Canada Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  35. Canada Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  36. Mexico Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  37. Mexico Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  38. Mexico Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  39. Europe Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  40. Europe Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  41. Europe Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  42. Germany Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  43. Germany Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  44. Germany Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  45. France Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  46. France Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  47. France Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  48. Sweden Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  49. Sweden Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  50. Sweden Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  51. Netherlands Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  52. Netherlands Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  53. Netherlands Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  54. U.K. Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  55. U.K. Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  56. U.K. Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  57. Italy Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  58. Italy Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  59. Italy Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  60. Spain Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  61. Spain Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  62. Spain Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  63. Turkey Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  64. Turkey Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  65. Turkey Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  66. Switzerland Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  67. Switzerland Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  68. Switzerland Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  69. Belgium Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  70. Belgium Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  71. Belgium Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  72. Asia Pacific Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  73. Asia Pacific Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  74. Asia Pacific Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  75. Japan Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  76. Japan Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  77. Japan Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  78. China Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  79. China Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  80. China Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  81. India Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  82. India Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  83. India Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  84. South Korea Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  85. South Korea Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  86. South Korea Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  87. Australia Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  88. Australia Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  89. Australia Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  90. Singapore Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  91. Singapore Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  92. Singapore Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  93. Malaysia Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  94. Malaysia Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  95. Malaysia Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  96. Thailand Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  97. Thailand Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  98. Thailand Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  99. Indonesia Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  100. Indonesia Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  101. Indonesia Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  102. Philippines Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  103. Philippines Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  104. Philippines Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  105. South America Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  106. South America Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  107. South America Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  108. Brazil Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  109. Brazil Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  110. Brazil Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  111. Argentina Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  112. Argentina Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  113. Argentina Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  114. Colombia Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  115. Colombia Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  116. Colombia Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  117. Middle East and Africa Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  118. Middle East and Africa Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  119. Middle East and Africa Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  120. Saudi Arabia Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  121. Saudi Arabia Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  122. Saudi Arabia Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  123. UAE Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  124. UAE Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  125. UAE Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  126. Egypt Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  127. Egypt Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  128. Egypt Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  129. Nigeria Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  130. Nigeria Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  131. Nigeria Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)
  132. South Africa Antibiotic Resistance  Market, By Disease, 2015–2025 (USD Billion)
  133. South Africa Antibiotic Resistance  Market, By Pathogen, 2015–2025 (USD Billion)
  134. South Africa Antibiotic Resistance  Market, By Drug Class, 2015–2025 (USD Billion)

 

List of Figures 

  1. Global Antibiotic Resistance  Market Segmentation
  2. Antibiotic Resistance  Market: Research Methodology
  3. Market Size Estimation Methodology: Bottom-Up Approach
  4. Market Size Estimation Methodology: Top-Down Approach
  5. Data Triangulation
  6. Porter’s Five Forces Analysis
  7. Value Chain Analysis
  8. Global Antibiotic Resistance  Market attractiveness analysis by Disease
  9. Global Antibiotic Resistance  Market attractiveness analysis by Pathogen
  10. Global Antibiotic Resistance  Market attractiveness analysis by Drug Class
  11. Global Antibiotic Resistance  Market attractiveness analysis by Region
  12. Global Antibiotic Resistance  Machine Market: Dynamics
  13. Global Antibiotic Resistance  Market Share by Diseases (2017 & 2025)
  14. Global Antibiotic Resistance  Market Share by Pathogens (2017 & 2025)
  15. Global Antibiotic Resistance  Market Share by Drug Class (2017 & 2025)
  16. Global Antibiotic Resistance  Market Share by Regions (2017 & 2025)
  17. Global Antibiotic Resistance  Market Share by Company (2018)



Please fill the form below, to recieve the report sample

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*

Please fill the form below for enquiry

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*
   Our Clients
  • \
   Payment Mode



For More Information

   For More Information

If you have any query? Please contact us

sales@fiormarkets.com
+1-201-465-4211


Copyright © 2019 Fior Market Research LLP, All Rights Reserved.